The combined analysis of the randomized Tamoxifen and Exemestane Trial (TEXT) and the Suppression of Ovarian Function Trial (SOFT) sought to determine the benefit of the addition of OFS to either tamoxifen or exemestane, an aromatase inhibitor, in premenopausal women with early-stage ER+ breast cancer. The gene discussed is CYP19A1; the disease is breast cancer.